Insurance Co Name

Insurance Co Address

May 10, 2019

Re: Name: Patient Name

DOB: Enter date of birth

Account #: Enter insurance company account number

To Whom It May Concern:

This letter is to support an appeal for choose a reason Lyrica® (pregabalin) for my patient, enter patient namefor the management of choose his/her multiple sclerosis.

Lyrica is medically necessary for my patient, enter patient name. choose he/she has tried click here to enter all previous treatments, which have not been able to effectively manage choose her/his. pain. Enter patient name has been on Lyrica for enter number of months months and has had a significant reduction in pain level. Prior to starting Lyrica, choose her/his pain level was enter number 0-10/10 and is now enter number 0-10/10 while taking Lyrica.

As described in the enclosed publication of the National Multiple Sclerosis Society, pain in MS is poorly recognized and often under-treated. It can also be more difficult to treat successfully than other symptoms of the disease. Pain in MS can result from damage to pathways in the brain and spinal cord. Lyrica is approved by the US Food and Drug Administration (FDA) for neuropathic pain that results from spinal cord injury. A growing body of evidence supports the use of anti-epileptic agents, including pregabalin (Lyrica), for the treatment of various pain syndromes associated with MS.

In addition to the 40+ citations supporting the National MS Society’s bulletin on MS-related pain, O’Connor and Dworkin’s 2009 review cites calcium channel alpha (2)-delta ligands (i.e., pregabalin) as recommended for first line treatment of neuropathic pain supported by randomized clinical trials.1 Additionally, Pollman and Feneberg’s 2008 review of the current management of pain in MS highlights the use of these same agents in a variety of MS-related pain syndromes.2

Lyrica is medically necessary for my patient, enter patient name. I respectfully request that you choose consider/reconsider coverage for this patient. Thank you in advance for your timely response.

Sincerely,

Click or tap here to enter text.

Click or tap here to enter text.

Click or tap here to enter text.

1O'Connor AB, Dworkin RH. (2009). Treatment of neuropathic pain: an overview of recent guidelines*. Am J Med*. 122(10 Suppl), S22-32. doi: 10.1016/j.amjmed.2009.04.007

2Pöllmann W, Feneberg W. (2008). Current management of pain associated with multiple sclerosis*. CNS Drugs*. 22(4), 291-324. DOI: 10.2165/00023210-200822040-00003